Literature DB >> 6584595

Cytocidal effect of gossypol on cultured murine erythroleukemia cells is prevented by serum protein.

H C Haspel, Y F Ren, K A Watanabe, M Sonenberg, R E Corin.   

Abstract

The interaction of gossypol (G) with cultured murine erythroleukemia cells (MELC) was studied in vitro. G was cytocidal (inhibited growth greater than 90%) to MELC at greater than 10 microM, but not at less than 5 microM in medium supplemented with 10 and 15% fetal calf serum (FCS). Five micromolar of G was cytocidal in 2 and 5% FCS. Serum albumin (2%) also decreased the effective cytocidal dose of G. This inhibition was reversible if extracellular drug (30 microM) was removed after 1 h but not after 24 h. Uptake of [14C]G by MELC (approximately 10(6) cells/ml) was saturable with half-maximal uptake at 8 microM in the absence of FCS. This uptake was concentrative, i.e., 75-fold relative to the total [14C]G concentration. In the presence of both FCS (approximately 2%) and serum albumin (approximately 0.03%), the accumulation of [14C]G (10 microM) by MELC was decreased approximately 50%. Direct binding of G to albumin, assayed by quenching of intrinsic fluorescence, was stoichiometric with respect to micromolar albumin content suggesting an apparent affinity of approximately 10(-7) M. Visible absorption spectra for G in the presence of serum albumin exhibited batho- and hyperchromic shifts of the maxima at approximately 380 nm. These studies demonstrate that: 1) G, at pharmacologically relevant concentrations, is cytocidal for MELC; 2) serum protein, e.g., albumin, can reduce both the cytocidal effects of G and the uptake of [14C]G by MELC; and 3) these effects are probably the result of G binding to serum protein, e.g., albumin, which reduces the free effective concentration of the drug.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6584595

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

Review 1.  An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agent and in gynaecological disease.

Authors:  D Wu
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

2.  Gossypol-induced damage to mitochondria of transformed Sertoli cells.

Authors:  J M Robinson; N Tanphaichitr; A R Bellvé
Journal:  Am J Pathol       Date:  1986-12       Impact factor: 4.307

3.  Cytotoxicity of crotoxin on murine erythroleukemia cells in vitro.

Authors:  R E Corin; L J Viskatis; J C Vidal; M A Etcheverry
Journal:  Invest New Drugs       Date:  1993-02       Impact factor: 3.850

4.  A preliminary clinical study of gossypol in advanced human cancer.

Authors:  R C Stein; A E Joseph; S A Matlin; D C Cunningham; H T Ford; R C Coombes
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells.

Authors:  M Ligueros; D Jeoung; B Tang; D Hochhauser; M M Reidenberg; M Sonenberg
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Cytotoxicity of enantiomers of gossypol.

Authors:  A E Joseph; S A Matlin; P Knox
Journal:  Br J Cancer       Date:  1986-09       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.